PLANTATION, Fla., Dec. 20 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA; VRA.U; VRA.WS) today announced that Dawson James Securities'
Director of Research, Stephen M. Dunn, initiated research coverage with a
"Speculative Buy" rating.
A copy of the report may be obtained by contacting:
Dawson James Securities
925 South Federal Highway
Boca Raton, FL 33432
Toll-free Phone: (866) 928-0928
Direct Phone: (561) 208-2929
The Dawson James research report was prepared by Dawson James
Securities, Inc. and the opinions, recommendations, estimates and/or
forecasts contained in the report are those of Dawson James Securities,
Inc. and not necessarily those of Viragen. The reference to the Dawson
James research report does not signify Viragen's endorsement or adoption of
the report or its concurrence with the information contained therein.
Viragen assumes no responsibility for the accuracy or adequacy of the
report, or any obligation to comment upon or update the report should all
or any portion of the report be or become inaccurate.
About Viragen, Inc.:
With international operations in the U.S., Scotland and Sweden, we are
a bio-pharmaceutical company engaged in the research, development,
manufacture and commercialization of therapeutic proteins for the treatment
of cancers and viral diseases. Our product and product candidate portfolio
includes: Multiferon(R) (multi-subtype, human alpha interferon) uniquely
positioned in valuable niche indications, such as high-risk malignant
melanoma, other niche cancer indications and selected infectious diseases;
VG101, a humanized monoclonal antibody that binds selectively to an antigen
over-expressed on Stage IV malignant melanoma tumors; and VG102, a highly
novel humanized monoclonal antibody that binds selectively to an antigen
that is over- expressed on nearly all solid tumors. We are also pioneering
the development of the OVA(TM) System (Avian Transgenics), with the
renowned Roslin Institute, the creators of "Dolly the Sheep", as a
revolutionary manufacturing platform for the large-scale, efficient and
economical production of human therapeutic proteins and antibodies, by
expressing these products in the egg whites of transgenic hens.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements
that can be identified by such terminology such as "believes," "expects,"
"potential," "plans," "suggests," "may," "should," "could," "intends," or
similar expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results to be materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally;
the Company's ability to obtain or maintain patent and other proprietary
intellectual property protection; and competition in general.
Forward-looking statements speak only as to the date they are made. The
Company does not undertake to update forward-looking statements to reflect
circumstances or events that occur after the date the forward-looking
statements are made.
Dawson James Securities has received investment banking compensation
from Viragen, as Dawson James recently acted as the underwriter for a
public offering of Viragen's Amex-listed Units. Additional disclosures are
contained in the report.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com/
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications of
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
